Hematopoietic Cell Transplantation after Solid Organ Transplantation

Area of Science:

• Medical Science
• Transplantation Medicine
• Hematology

Background:

• Serial transplantation (Solid Organ Transplantation [SOT] followed by Hematopoietic Cell Transplantation [HCT]) addresses single diseases with multiorgan involvement or separate conditions.
• Previous reports on serial transplants are limited, primarily consisting of single case studies.
• This study reviews previously published and new institutional data on SOT followed by HCT.

Purpose of the Study:

• To summarize and analyze outcomes of patients undergoing HCT after SOT.
• To evaluate the feasibility and safety of serial transplantation.
• To assess the incidence of rejection in patients receiving both SOT and HCT.

Main Methods:

• Systematic review of 13 autologous and 27 allogeneic HCTs post-SOT from existing literature.
• Detailed analysis of 16 additional patients (8 autologous, 8 allogeneic HCTs) from a single institution.
• Survival analysis and assessment of rejection rates for both solid organ and hematopoietic cell grafts.

Main Results:

• Five of 8 autologous HCT recipients survived a median of 4.6 years post-HCT.
• Four of 8 allogeneic HCT recipients survived a median of 8.7 years post-HCT.
• Serial transplantation demonstrated feasibility with low rates of solid organ and hematopoietic cell rejection in carefully selected patients.

Conclusions:

• Hematopoietic cell transplantation following solid organ transplantation is a viable therapeutic option for select patient populations.
• The combined approach is associated with encouraging long-term survival.
• Careful patient selection is crucial for minimizing rejection risks in serial transplantation.